Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051298
Status:
COMPLETED
Last Update Posted:
2007-06-12
First Post:
2003-01-07
Brief Title:
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to determine the efficacy how well the drug works safety and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-MC-HGIN | None | None | None |